Smart Care Based on Telemonitoring and Telemedicine for Type 2 Diabetes Care: Multi-Center Randomized Controlled Trial.
Source: Jeong, J. Y., et al. 2018 - Pubmed ID: 29341843
Setting: South Korea, 4 university hospitals
RCT
Follow up: 24 weeks
Sample size:
Total: 338 (299)
Telemonitoring: 113 (99)
Telemedicine: 112 (99)
CG: 113 (101)
Inclusion criteria:
- Diabetes type 2
- HbA1c ranging from 7-11%
Home monitoring
- Web enabled computer
- Specific software
- Glucometer
- Body composition analyzer
Video consultation
Intervention: Tele monitoring – Pt. performs measures on clinical data by using home monitoring equipment. Reports to endocrinologist after 8, 16, 24 weeks on scheduled outpatient appointment. Telemedicine – Instead of outpatient visits on hospital, patients contacted physicians from their equipment.
Duration: 24 weeks
Add on: –
Control group: Conventional care
Clinical effect:
- HbA1c →
- HbA1c target (≤7%) →
- Cholesterol →
- Weight →
- BMI →
- Blood pressure →
Patient safety: Adverse events were reported in 33, 30 and 23 patients in the control, telemonitoring, and telemedicine groups, respectively, and adverse events related to complications of diabetes in seven, seven, and three patients, respectively
Patient experiences: NA
Staff experiences: NA
Investment:
Equipment/Materials
- Computer
- Glucometer
Running:
Staff resources
- Online communication with patients
Organization: NA
Health care utilization: NA